Intravenous salbutamol bolus compared with an aminophylline infusion in children with severe asthma: a randomised controlled trial

G Roberts, D Newsom, K Gomez, A Raffles, S Saglani, J Begent, P Lachman, K Sloper, R Buchdahl, A Habel on behalf of the North West Thames Asthma Study Group

Background: The relative efficacies of aminophylline and salbutamol in severe acute childhood asthma are currently unclear. A single bolus of salbutamol was compared with a continuous aminophylline infusion in children with severe asthma in a randomised, double blind study.

Methods: Children aged 1–16 years with acute severe asthma were enrolled if they showed little improvement with three nebulisers (combined salbutamol and ipratropium) administered over an hour and systemic steroids. Subjects were randomised to receive either a short intravenous bolus of salbutamol (15 µg/kg over 20 minutes) followed by a saline infusion or an aminophylline infusion (5 mg/kg over 20 minutes) followed by 0.9 mg/kg/h.

Results: Forty four subjects were enrolled, with 18 randomly allocated to receive salbutamol and 26 to receive aminophylline. The groups were well matched at baseline. An intention to treat analysis showed that there was no statistically significant difference in the asthma severity score (ASS) at 2 hours between the two groups (median [IQR] 6 [6, 8] and 6.5 [5, 8]) for salbutamol and aminophylline respectively, p=0.93). A similar improvement in ASS to 2 hours was seen in the two groups (mean difference –0.08, 95% CI –0.97 to 0.80). There was a trend (p=0.07) towards a longer duration of oxygen therapy in the salbutamol group (17.8 hours [95% CI 8.5 to 37.5] v 15.0 hours [95% CI 3.4 to 14.2], and a significantly (p=0.02) longer length of hospital stay in the salbutamol group (85.4 [95% CI 66.1 to 110.2] hours v 57.3 hours [95% CI 45.6 to 72.0]). There was no significant difference in adverse events between the two groups.

Conclusions: This study suggests that, in severe childhood asthma, there is no significant difference in the effectiveness of a bolus of salbutamol and an aminophylline infusion in the first 2 hours of treatment. Overall, the aminophylline infusion was superior as it significantly reduced the length of stay in hospital.

Thorax 2003;58:306–310
University Hospital. Study numbers were assigned to aminophylline or salbutamol according to a random number table. Each centre had its own sequence of numbers to ensure that each enrolled similar numbers into each group. Subjects were treated with the next serially numbered treatment pack. Only one investigator (GR), who had no involvement in the enrolment or clinical care of any subject, was aware of this allocation. Blood was taken 1 hour after starting intravenous infusion rate. For subjects in the salbutamol arm, the drug levels were assayed centrally and checked by one investigator (GR), who had no involvement in the allocation. Blood was taken 1 hour after starting intravenous treatment to determine when supplementary oxygen was no longer required to keep the saturations at 92% or above (Ohmeda 3800). Subjects were taken off oxygen for 5 minutes before the measurement. Where the saturation dropped below 85%, the oxygen was restarted and the reading recorded as less than 85%. Peak expiratory flow measurements were not routinely recorded as most of the subjects were unable to perform this because of their age or the severity of the exacerbation. Adverse effects were recorded. All outcome measures were recorded by staff who were unaware of the subject’s allocation.

### Statistical methods

An intention to treat analysis was undertaken. The ASS in each group after 2 hours of treatment was compared using a Wilcoxon rank sum test (early primary end point). The change in the ASS from baseline to 2 hours was normally distributed; it was calculated that the data from 42 subjects would be sufficient to detect a 30% difference in change in severity score at 2 hours between the two groups assuming a standard deviation of 30% of the ASS, 90% power, and a 5% level of significance. An interim analysis was undertaken by one investigator (GR) after 21 subjects had been randomised, one because of their age or the severity of the exacerbation. Adverse events were recorded. All outcome measures were recorded by staff who were unaware of the subject’s allocation.

#### Outcome measures

The ASS was assessed just before the start of intravenous treatment and at 1, 2, 6, 12, and 24 hours. Ventilated subjects were given an ASS of 9. The 9-point ASS was validated within the study; the mean difference (range) in the score assigned by each of two observers was 0.1 (–1 to +1). Prior to analysis, the clinician was instructed to adjust the nebuliser to maintain, increase, or reduce the rate at random to maintain blinding. All subjects were also treated with systemic corticosteroids, nebulised salbutamol as required, and 6 hourly nebulised ipratropium. Nebulised and intravenous treatment was reduced according to a regime based on the ASS as follows: score ≤5, no additional treatment required; score >5 and ≤7, continuous nebulisation; 6, nebulisation half hourly; 5, nebulisation hourly; 4, nebulisation every 2 hours; score >7, continuous oxygen, 4 hourly treatment and infusion stopped. Where the nebulisation stopped as tachycardic and hypoglycaemic (1).
RESULTS

Subjects and treatment allocation

Sixty children were admitted with severe asthma during a cumulative recruitment period of 97 months at the five hospitals, 44 of whom were enrolled into the study (fig 1). Eighteen subjects (40.9%) were randomly allocated to treatment with a bolus of salbutamol and 26 (59.1%) to an aminophylline infusion. There were no significant differences in the baseline demographic characteristics of these subjects, in their previous asthma history or presenting exacerbation (table 1).

For the final analysis. All statistical tests were undertaken using Stata 6.

Asthma severity score

Using an intention to treat analysis, there were no significant differences in the ASS for each group either before the commencement of the intravenous bronchodilator or in the following 24 hours (table 2, fig 2). The difference in the change in ASS between the aminophylline and salbutamol groups was –0.08 (95% CI –0.97 to 0.80), table 2. This result was unchanged when the early withdrawals were excluded.

Supplementary oxygen

There was no difference in the proportions requiring supplementary oxygen or the saturation in air before intravenous treatment (table 2) or at any time in the subsequent 24 hours (fig 3). Subjects in the aminophylline and salbutamol groups required supplementary oxygen for 7.0 hours (95% CI 3.4 to 14.2) and 17.8 hours (8.5 to 37.5), respectively (table 2). The salbutamol group therefore required supplementary oxygen for 2.56 times longer (95% CI 0.92 to 7.18) using an intention to treat analysis. Exclusion of the early withdrawals from the analysis did not change the result.

Additional therapy

The intravenous study medication ran for similar lengths of time in the salbutamol and aminophylline groups (table 2). The use of nebulised salbutamol was also similar in the two groups with at least hourly treatment for the first 6 hours.

Table 1 Baseline characteristics of study subjects

<table>
<thead>
<tr>
<th>Item</th>
<th>Salbutamol (n=18)</th>
<th>Aminophylline (n=26)</th>
<th>p value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>M:F (%) males</td>
<td>12.6 (66.7%)</td>
<td>20.6 (76.9%)</td>
<td>0.45</td>
</tr>
<tr>
<td>Age (years)</td>
<td>3.85 (1.35, 15.55)</td>
<td>4.12 (1.19, 13.13)</td>
<td>0.80</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>15.0 (12.0, 30.4)</td>
<td>16.8 (12.5, 30.0)</td>
<td>0.83</td>
</tr>
<tr>
<td>Age at which asthma diagnosed (years)</td>
<td>2.00 (1.00, 2.75)</td>
<td>1.25 (1.00, 2.75)</td>
<td>0.63</td>
</tr>
<tr>
<td>No of previous admissions with asthma</td>
<td>1 (0, 2)</td>
<td>1 (0, 4)</td>
<td>0.54</td>
</tr>
<tr>
<td>Previous intravenous therapy for asthma</td>
<td>4 (22.2%)</td>
<td>4 (15.4%)</td>
<td>0.70</td>
</tr>
<tr>
<td>Previous ventilatory support for asthma</td>
<td>1 (5.6%)</td>
<td>1 (3.9%)</td>
<td>1.00</td>
</tr>
<tr>
<td>No with eczema</td>
<td>8 (88.8%)</td>
<td>8 (72.7%)</td>
<td>1.00</td>
</tr>
<tr>
<td>Duration of exacerbation (hours)</td>
<td>24 (24.72)</td>
<td>24 (24.48)</td>
<td>0.36</td>
</tr>
<tr>
<td>Treatment with nebulised β agonists before presentation</td>
<td>2 (11.1%)</td>
<td>4 (20.0%)</td>
<td>0.68</td>
</tr>
<tr>
<td>Duration of treatment with systemic corticosteroids pre-study bolus (hours)</td>
<td>3.0 (0.5, 10.9)</td>
<td>0.0 (0.0, 3.5)</td>
<td>0.06</td>
</tr>
<tr>
<td>ASS on admission</td>
<td>8 (6, 9)</td>
<td>9 (7, 9)</td>
<td>0.45</td>
</tr>
<tr>
<td>ASS at start of study bolus</td>
<td>8 (7, 8)</td>
<td>8 (7, 9)</td>
<td>0.76</td>
</tr>
<tr>
<td>Saturation in air on admission</td>
<td>87.5% (&lt;84.0, 91.0)</td>
<td>90.0% (87.0, 94.0)</td>
<td>0.26</td>
</tr>
<tr>
<td>Saturation in air at start of study bolus</td>
<td>91.0% (88.5, 93.5)</td>
<td>91.0% (88.0, 93.0)</td>
<td>0.77</td>
</tr>
<tr>
<td>Need for supplementary oxygen at start of trial bolus</td>
<td>14 (77.8%)</td>
<td>19 (79.2%)</td>
<td>0.91</td>
</tr>
</tbody>
</table>

Values are medians with interquartile ranges or proportions. *Comparison of subjects in each group using unpaired t test (change in ASS, duration of oxygen and infusion, and time to discharge) or Wilcoxon rank sum test; proportions compared with χ² or Fisher’s exact test as appropriate.

Table 2 Progress of study subjects

<table>
<thead>
<tr>
<th>Item</th>
<th>Salbutamol (n=18)</th>
<th>Aminophylline (n=26)</th>
<th>Difference (95% CI)</th>
<th>p value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asthma severity score (ASS) at 2 hours</td>
<td>6 (0.37)</td>
<td>6.5 (0.33)</td>
<td>0.5 (–)</td>
<td>0.93</td>
</tr>
<tr>
<td>Change in ASS from time 0 to 2 hours</td>
<td>–1.11 (0.39)</td>
<td>–1.19 (0.25)</td>
<td>–0.08 (–0.97 to 0.80)</td>
<td>0.85</td>
</tr>
<tr>
<td>Duration of oxygen therapy (hours)</td>
<td>17.8 (8.9)</td>
<td>20.0 (6.1)</td>
<td>2.56 times longer (0.92 to 7.18)</td>
<td>0.07</td>
</tr>
<tr>
<td>Duration of infusion (hours)</td>
<td>32.2 (3.2)</td>
<td>27.8 (0.85)</td>
<td>–4.4 (–2.0 to 14.8)</td>
<td>0.41</td>
</tr>
<tr>
<td>Time to discharge (hours)</td>
<td>85.4 (13.2)</td>
<td>71.3 (8.3)</td>
<td>1.49 times longer (1.06 to 2.10)</td>
<td>0.02</td>
</tr>
</tbody>
</table>

Values for the salbutamol and aminophylline groups are presented with standard errors (SE). *Comparison of subjects in each group using unpaired t test (change in ASS, duration of oxygen and infusion, and time to discharge) or Wilcoxon rank sum test (ASS at 2 hours). All subjects included in the intention to treat analysis.
Intravenous salbutamol bolus v aminophylline infusion in severe paediatric asthma

Figure 3 Percentage requiring supplementary oxygen to maintain saturations at 92% or above in the salbutamol (dotted line) and aminophylline (continuous line) groups.

(data not shown). Five (27.8%) subjects from the salbutamol group and four (15.4%) subjects from the aminophylline group required additional infusions of aminophylline, salbutamol, or magnesium sulphate. Two subjects (11%) in the salbutamol group and one (4%) in the aminophylline group also required ventilation. All responded to further treatment. Thirteen (72.2%) subjects in the salbutamol group and 20 (84.6%) in the aminophylline group required no additional treatment. There were no significant differences in the demographic details, asthma history, or presenting features before the commencement of the intravenous bolus between subjects requiring additional treatment and the other subjects (data not shown).

Discharge
There was a significant difference (p=0.02) in the time from the commencement of intravenous treatment to discharge from hospital in the two groups (table 2), with the duration of inpatient treatment for the salbutamol group being 1.49 times longer (95% CI 1.06 to 2.10) than the aminophylline group.

Adverse events
The most frequent adverse events were nausea, vomiting, and abdominal pain. There were no significant differences in the number of adverse events reported by the salbutamol and aminophylline groups (22.2% v 36%, p=0.50, Fisher's exact test). There was no significant change in the mean serum potassium level with either intravenous treatment; 5–10% of subjects had a serum potassium level <3 mmol before starting either intravenous bronchodilator and a similar proportion were hypokalaemic in the few hours after starting intravenous treatment (data not shown).

DISCUSSION
In this study we have compared an intravenous bolus of salbutamol with an infusion of aminophylline in a population of children with severe acute asthma that was unresponsive to maximal nebulised treatment and systemic corticosteroids. The results show that there was no statistically significant difference in the effectiveness of these two regimes after 2 hours, although overall the aminophylline infusion appeared superior as it reduced the length of stay in hospital.

A recent Cochrane review compared aminophylline with placebo in children with severe acute asthma receiving treatment with inhaled bronchodilators and systemic glucocorticoids. It showed that aminophylline improves lung function, reduces clinical severity, and reduces the need for ventilation. This is contrary to the results of a previous meta-analysis of adult studies. The largest study included in the Cochrane review was by Yung et al which contributed 163 of the 380 cases and was the only one to show a measurable benefit. Like the study by Yung et al, our investigation enrolled subjects only if they had a severe exacerbation of asthma. This suggests that subjects with less severe exacerbations improve regardless of whether they receive additional intravenous treatment, and that the relatively small improvement in lung function produced by an aminophylline infusion is therefore only beneficial to children with the most severe exacerbations. The study presented here also showed that the group receiving aminophylline had a 30% shorter stay in hospital. This has significant implications for health service resources as well as the child's well being, given that an aminophylline infusion appears to shorten the admission time by more than a day.

A second Cochrane review which examined the addition of intravenous salbutamol in severe acute asthma in adults and children found that it afforded no additional benefit over inhaled treatment or placebo. These conclusions are flawed for a number of reasons; 80% of the included studies were published before 1990 when lower doses of intravenous β2 agonists were used compared with those currently in use. The review states that there are insufficient paediatric studies to provide subgroup comparisons. This is important as children with asthma behave differently from adults as atopy is a more common feature and they do not have concurrent chronic obstructive airway disease or ischaemic heart disease. All but one of the studies in the Cochrane review used suboptimal concurrent nebulised therapy. The two adequately sized randomised controlled trials in children show that intravenous salbutamol is effective. Brown et al enrolled subjects who failed to improve after one dose of nebulised salbutamol. A bolus of intravenous salbutamol or placebo was followed by frequent nebulised therapy. A significant improvement in the ASS occurred within 2 hours, together with earlier discharge from hospital. Intravenous salbutamol may be able to reach the obstructed airways seen in severe exacerbations of asthma, thereby allowing nebulised agents to reach them.

Intravenous aminophylline and β2 agonist have only been compared in severe acute childhood asthma in one study. This study used very small intravenous dosages, gave no concurrent nebulised therapy, and enrolled insufficient subjects to detect anything but a major difference. The adult studies addressing this issue are similarly flawed. Using the currently recommended intravenous dosages and frequency of concurrent nebulised therapy, we have shown that an aminophylline infusion is more effective than a single bolus of salbutamol. Only three quarters of the salbutamol group recovered with a single bolus, which is disappointing as a bolus of salbutamol is an attractive option for the busy paediatric emergency department. The subjects enrolled into the study by Browne et al had only been treated with one dose of nebulised salbutamol whereas our patients had failed to improve with three doses of nebulised salbutamol and ipratropium. It is therefore perhaps not surprising that, unlike Browne et al, we failed to show that a single bolus of salbutanmol was more effective than aminophylline. It is possible, however, that a proportion of these non-responders would have improved after a further bolus or a continuous infusion of salbutamol.

This study has several limitations. It is relatively small, although we were still able to demonstrate equivalence after 2 hours and a significant difference in duration of admission. The 95% confidence interval for the difference in improvement in ASS to 2 hours between the two groups was –0.97 to 0.80. Given that the ASS is a 9 point scoring system, the difference in efficacy between the two treatments is minimal within this time frame. A larger study would have enabled a comparison of other important outcome measures such as the need for mechanical ventilation, although with only 11% and 4% requiring ventilation in the salbutamol and aminophylline groups, respectively, a few hundred subjects would have had to be enrolled to address this issue successfully. Although there was an imbalance in the allocation between the two groups, this did not adversely reduce the statistical power of the study.
We included subjects who satisfied the clinical severity score, regardless of whether or not they required supplementary oxygen. This reduced the number of subjects available to determine the relative length of supplementary oxygen therapy, which probably prevented this point reaching significance. Aminophylline levels were only assayed after 1 hour of treatment when many of the subjects had levels below the quoted therapeutic range. They had, however, received the standard aminophylline loading dose.” It is perhaps significant that the two studies which showed that aminophylline is effective used a higher bolus dose. However, we have shown that an infusion of aminophylline is more effective than a bolus of salbutamol. As we did not provide a protocol for treating subjects who failed to improve with the study medication, we were unable to examine systematically the role of adding the other bronchodilator or additional agents such as magnesium sulphate.

The consensus for treating severe acute asthma is currently moving from intravenous aminophylline towards intravenous β agonist. This is despite the paucity of randomised controlled trials incorporating current dosages of intravenous bronchodilators and frequent nebulised therapy in the paediatric age group. This study is helpful in informing the debate on the relative merits of intravenous salbutamol and aminophylline and whether salbutamol should be used as a bolus or infusion. It shows that there is no statistically significant difference in the effectiveness of intravenous salbutamol and aminophylline over the first 2 hours of treatment. Overall, the infusion of aminophylline was more effective with a significant reduction in the duration of admission and a trend towards a shorter duration of supplementary oxygen. Adverse effects did not appear to be significantly greater in the aminophylline group. Further clinical studies are required to determine whether multiple intravenous boluses of salbutamol are as effective as an aminophylline infusion, to evaluate the relative effectiveness of infusions of salbutamol and aminophylline, and to investigate whether these two intravenous bronchodilators are synergistic in acute severe asthma.

ACKNOWLEDGEMENTS
The authors acknowledge the help of all the staff working at the five hospitals involved, particularly Andrea Thomas, Pippa Banister; Mitch Blair, Wouter Hanekom; Keith Brent, Nitha Naqvi, Julian Redhead, Kecia Taylor and Ranjan Suri; the statistical advice provided by Paul Bassett; and all the children and families involved without whom the study would not have been possible.

Authors’ affiliations
G Roberts, Imperial College School of Medicine at St Mary’s Hospital, London, UK
G Roberts, K Gomez, A Habel, West Middlesex Hospital
D Newsom, P Lachman, Northwick Park Hospital
A Raffles, S Saglani, J Begent, Queen Elizabeth II Hospital
K Sloper, Ealing Hospital
R Buchdahl, Hillingdon Hospital

DN had the original idea for the study. The protocol was developed by GR, DN and AH. All the authors were involved in entering subjects into the study and collecting data. GR undertook the data analysis and wrote the first draft of the paper. All the authors contributed to the revision of the paper. AH will act as guarantor of the paper.

This work was supported by funding from the NHS London Regional Office, Research & Development Programme. The views expressed in the publication are those of the authors and not necessarily of the NHS or the Department of Health.

REFERENCES
Intravenous salbutamol bolus compared with an aminophylline infusion in children with severe asthma: a randomised controlled trial
G Roberts, D Newsom, K Gomez, A Raffles, S Saglani, J Begent, P Lachman, K Sloper, R Buchdahl and A Habel

Thorax 2003 58: 306-310
doi: 10.1136/thorax.58.4.306

Updated information and services can be found at:
http://thorax.bmj.com/content/58/4/306

These include:

References
This article cites 15 articles, 5 of which you can access for free at:
http://thorax.bmj.com/content/58/4/306#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Asthma (1782)
- Drugs: respiratory system (526)
- Child health (843)
- Clinical trials (epidemiology) (557)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/